Aura Biosciences insider files initial Form 3

Aura Biosciences, Inc. filed an initial insider ownership report for Natalie C. Holles, who is identified as both a director and an officer.

Rhea-AI Filing Summary

Aura Biosciences, Inc. filed an initial insider ownership report for Natalie C. Holles, who is identified as both a director and an officer. The Form 3 data show no reported share purchases, sales, gifts, or option exercises, with all transaction counts and net share changes at zero.

Key Figures

Insider share purchases: 0 shares Insider share sales: 0 shares Net buy/sell shares: 0 shares +1 more

4 metrics

Insider share purchases 0 shares buyCount and buyShares in Form 3 transaction summary

Insider share sales 0 shares sellCount and sellShares in Form 3 transaction summary

Net buy/sell shares 0 shares netBuySellShares reported as neutral activity

Derivative transactions 0 transactions derivativeTransactionCount in Form 3 summary

Key Terms

Form 3, reporting person, transactionSummary

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3): initial insider ownership report"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

"The reporting person is Natalie C. Holles, listed as director and officer"

transactionSummary financial

"The transactionSummary shows all counts and netBuySellShares as 0"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aura Biosciences (AURA) disclose in this Form 3 filing?

Aura Biosciences disclosed an initial insider ownership report for Natalie C. Holles. The filing identifies her as a director and officer, and the summarized data show no share purchases, sales, gifts, or derivative exercises associated with this Form 3 submission.

Who is the reporting person in Aura Biosciences (AURA) Form 3?

The reporting person is Natalie C. Holles, listed as both a director and an officer of Aura Biosciences. Her officer title is referenced as “See Remarks,” and this specific dataset does not include any share transactions or derivative positions tied to her name.

Does Aura Biosciences’ Form 3 show any insider buying or selling?

No, the Form 3 data show zero insider buying or selling. The transaction summary lists buyCount, sellCount, acquireCount, disposeCount, and netBuySellShares all as 0, indicating no reported trading activity by the reporting person in this initial statement.

Are there any derivative positions reported in Aura Biosciences (AURA) Form 3?

No derivative positions are reported in this Form 3. The derivativeSummary is empty and derivativeTransactionCount is 0, indicating no options, warrants, or other derivative securities are listed for the reporting person in the provided data excerpt.

What does the netBuySellDirection field indicate in the Aura Biosciences Form 3?

The netBuySellDirection field is marked “neutral,” reflecting that netBuySellShares equals 0. This means the filing reports no net change in common share ownership from purchases or sales, consistent with the absence of any listed transactions in the summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 04:06 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Holles Natalie C.

(Last) (First) (Middle)

C/O AURA BIOSCIENCES, INC.

80 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/30/2026

3. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Chief Executive Officer and President. Exhibit 24.1 - Power of Attorney.

No securities are beneficially owned.

	/s/ Conor Kilroy, as Attorney-in-Fact	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)